A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 102.99
GOOG 532.71
MSFT 44.38
BAC 16.40
FB 78.37

Recently Added

NCLH 34.64
EXPR 14.32
ANF 32.79
TRP 47.48
TRGP 125.62

Gaining Speed

TRP 47.48
TRGP 125.62
EXPR 14.32
NCLH 34.64
ANF 32.79

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!